Who is sponsoring NCT00039000?

NCT00039000 is sponsored by Agenus Inc..

What condition does NCT00039000 study?

NCT00039000 studies Malignant Melanoma.

What drugs are being tested in NCT00039000?

Interventions: HSPPC-96 or Oncophage.

What is the status of NCT00039000?

NCT00039000 is currently COMPLETED.

Last reviewed 2012-09-06 · How we verify

A Phase III Study of Heat Shock Protein-Peptide Complex (HSPPC-96) Versus Physician's Choice Including Interleukin-2 and/or Dacarbazine/Temozolomide-based Therapy and/or Complete Tumor Resection in Stage IV Melanoma

NCT00039000 Phase 3 COMPLETED

The primary goal of this study is to determine if people with metastatic melanoma who receive Heat Shock Protein-Peptide Complex - 96 (HSPPC-96 or Oncophage) after surgery live longer than people who may or may not have surgery but who receive conventional chemotherapy including IL-2/DTIC. A second goal is to determine the safety and frequency of side effects in subjects who receive therapy with HSPPC-96.

Details

Lead sponsor	Agenus Inc.
Phase	Phase 3
Status	COMPLETED
Enrolment	350
Start date	2002-03
Completion	2005-12

Conditions

Malignant Melanoma

Interventions

HSPPC-96 or Oncophage

Countries

United States, Australia, Hungary, Italy, Poland, Russia, Sweden, Ukraine, United Kingdom